I paraphrased your very long praise of the drug candidate to indicate your clear preference for it. There's not a lot of nuance in that sort of perspective, unfortunately eg. a bizarrely optimistic idea that doctors will be looking to prescribe this over semaglutide for weight loss.
I don't disagree that the OSA market is very large and offers opportunities to many, but the rapidly changing role of other treatments is very relevant to a condition that is frequently treated by weight loss.
